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Abstract: The threat of antimicrobial resistance to society is compounded by a relative lack of
new clinically effective licensed therapies reaching patients over the past three decades. This has
been particularly problematic within antifungal drug development, leading to a rise in fungal
infection rates and associated mortality. This paper highlights the potential of an ultrashort
peptide, (naphthalene-2-ly)-acetyl-diphenylalanine-dilysine-OH (NapFFKK-OH), encompassing
hydrogel-forming and antifungal properties within a single peptide motif, thus overcoming
formulation (e.g., solubility, drug loading) issues associated with many currently employed highly
hydrophobic antifungals. A range of fungal susceptibility (colony counts) and cell cytotoxicity (MTS
cell viability, LIVE/DEAD staining® with fluorescent microscopy, haemolysis) assays were employed.
Scanning electron microscopy confirmed the nanofibrous architecture of our self-assembling peptide,
existing as a hydrogel at concentrations of 1% w/v and above. Broad-spectrum activity was
demonstrated against a range of fungi clinically relevant to infection (Aspergillus niger, Candida glabrata,
Candida albicans, Candida parapsilosis and Candida dubliniensis) with greater than 4 log10 CFU/mL
reduction at concentrations of 0.5% w/v and above. We hypothesise antifungal activity is due
to targeting of anionic components present within fungal cell membranes resulting in membrane
disruption and cell lysis. NapFFKK-OH demonstrated reduced toxicity against mammalian cells
(NCTC 929, ARPE-19) suggesting increased selectivity for fungal cells. However, further studies
relating to safety for systemic administration is required, given the challenges toxicity has presented
in the wider context of antimicrobial peptide drug development. Overall this study highlights the
promise of NapFFKK-OH hydrogels, particularly as a topical formulation for the treatment of fungal
infections relating to the skin and eyes, or as a hydrogel coating for the prevention of biomaterial
related infection.
Keywords: peptide; self-assembly; nanomaterial; hydrogel; aspergillosis; candidiasis
1. Introduction
Antimicrobial resistance is a severe and increasing threat to society. Overuse of and bacterial
resistance to antibiotics receives the majority of public attention; however, the emergence of fungi
resistant to multiple therapies has led to an urgent need for new, effective and safe antifungal
agents [1]. The incidences of fungal infection are increasing due to factors such as an ageing population,
increasing the prevalence of underlying disease (AIDS, cancer, diabetes) [2]. Modern medicine
has also contributed to an increase in fungal infections directly through the use of medical devices
(e.g., catheters), immunosuppressive therapies and antibiotics [3,4]. Candidiasis and aspergillosis are
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the two most common forms of fungal disease [5]. Candida is a yeast that exists primarily within the
gastrointestinal tract as a commensal microorganism. However, if the normal microflora is disturbed,
for example due to use of antibiotics, it becomes an opportunistic pathogen [6]. In the United Sates
Candida species are the fourth most common pathogen implicated in septicaemia and represent a
major source of nosocomial infections [7,8]. Aspergillus is a saprophytic filamentous mould, widely
distributed throughout the natural environment, commonly found in areas of damp and on decaying
vegetation. Their spores are widespread within air but only tend to cause infection in patients with
lowered immunity or damaged lungs. Aspergillus niger is also an opportunistic pathogen, leading
to serious infections such as pulmonary aspergillosis [9]. The severity of fungal septicaemia and the
importance of prevention or early treatment are highlighted by severe mortality rates. Between 30–50%
episodes of invasive aspergillosis and 50% of candidiasis result in death. Collectively, the two species
are responsible for more than 75% of all mortalities related to fungal infections [10,11].
Four major classes of antifungal drugs currently exist for the treatment of systemic fungal
infections: polyenes, pyrimidine analogues, echinocandins and triazoles [12,13]. Alternative antifungal
classes exist, for example allylamines and morpholines, but they can only be administered topically
due to poor systemic efficacy [14]. The most common antifungal drug for systemic infections is
amphotericin B, followed by triazoles such as fluconazole. The broad use of licensed antifungals
and relative lack of alternatives has contributed to an increase in antifungal resistance within these
species [12]. Currently licensed topical formulations encounter difficulties with delivering sufficient
cidal concentrations of antifungals to the site of infection, resulting in the survival and spread of fungal
populations more tolerant to drug therapy. This is due partly to the highly hydrophobic nature of
antifungal molecules, which are limited by the quantity that can be loaded into a topical formulation
base by physiochemical issues such as solubility [15].
Antimicrobial peptides have long been of interest to those involved in drug development as an
alternative class of therapies to relieve the burden of antimicrobial resistance [16]. Existing within
nature as mediators of the innate immune response, they are particularly promising given that they
possess multiple microbial targets, thereby reducing the chance of resistance development. Microbial
targets include fungal membranes and molecules involved within intracellular biomolecular processes
such as protein replication and DNA synthesis [17]. Key to antimicrobial efficacy and selectivity is the
hydrophobic: charge balance of the peptide motif, which ultimately defines membrane interactions and
surfactant-like activity [18]. Several peptides selectively target fungal cells. Echinocandins, including
caspofungin, micafungin and anidulafungin, are an existing class of licensed peptide antifungals that
inhibit β-(1,3)-glucan synthase, responsible for the production of β-(1,3)-glucan essential for fungal cell
wall integrity [19]. The cationic human salivary peptide histatin-5 is capable of producing reactive oxygen
species and binds to fungal membrane receptors, entering cells to target mitochondria and resulting in
fungal cell death [20,21].
An interesting group of peptides have the ability to assemble into defined nanomaterial architectures,
including nanofibers and nanotubes, in response to changes in physiological stimuli, including pH, ionic
strength, temperature and the presence of specific enzymes [22]. Of particular promise to antimicrobial
drug delivery is the ability of these peptides to assemble into supramolecular hydrogels composed of
nanofibres. Our group has been successful in designing a variety of ultrashort peptide motifs (≤7 amino
acids) that demonstrate inherent hydrogel forming capability and antimicrobial activity within a single
molecular motif [23–25]. This overcomes the formulation issues associated with current topical therapies,
whereby the quantity of drug loaded into a hydrogel base is restricted by drug solubility and disruption
of the hydrogel’s mechanical properties. Antimicrobial peptide hydrogels have the potential for future
application within the areas of anti-infective biomaterials and wound healing. However, peptide gels
have not been studied for possible use within antifungal applications. This paper will outline the
antifungal efficacy of our (naphthalene-2-ly)-acetyl-diphenylalanine-dilysine-OH (NapFFKK-OH) motif
(Figure 1) as a peptide hydrogel therapy against a variety of fungal pathogens including Aspergillus niger,
Candida albicans, Candida glabrata, Candida dubliniensis and Candida parapsilosis.
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Figure 1. Chemical structure of NapFFKK-OH hydrogelator.
2. Results and Discussion
2.1. Hydrogel Formation and Characterisation
As previously demonstrated by our group, NapFFKK-OH was shown to form hydrogels at
concentrations of 1% w/v and above using a formulation method of pH induction [23]. Scanning
electron microscopy (SEM) images (Figure 2) confirmed NapFFKK-OH hydrogels were of nanofibrous
architecture despite the presence of some drying artefacts due to flash freezing of the hydrogel
formulation. These are formed by intermolecular interactions, primarily pi–pi and Van der Waal’s,
between phenyl groups within the naphthalene and phenylalanine subunits. NapFFKK-OH hydrogels
demonstrate random entanglements of densely packed three-dimensional fibres formed from β-sheet
peptide secondary structures commonly observed for ultrashort peptide motifs based on the
diphenylalanine (FF) sequence. Our group has previously characterized rheological properties of
NapFFKK-OH, demonstrating its rigid mechanical properties typical of a self-supporting gel, with
storage moduli (G′) observed to be larger than loss moduli (G”) by at least an order of magnitude
(G′ = 200 Pa, G′′ = 20 Pa, 2% w/v) [23,26].
Figure 2. SEM images of 2% w/v NapFFKK-OH peptide at (a) 100× magnification, scale bar = 100 µm;
(b) 2000×magnification, scale bar = 100 µm.
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2.2. Fungal Susceptibility
The antifungal activity of NapFFKK-OH was assessed after incubation with a range of clinically
relevant pathogens commonly presenting in immunocompromised patients with fungal infections.
These included Aspergillus niger (Figure 3) and four separate species of Candida (glabrata, albicans,
parapsilosis and dubliniensis) (Figures 4–7, Figure S4 and Figure S5) from a mixture of reference strains
(i.e., ATCC, NCTC, CABI, NCYC) and clinical isolates of Candida dubliniensis sampled from the
oral cavity of diabetic (DC24 9) and non-diabetic (NDC19) patients. Significant reduction in fungal
viability, measured as log10 colony forming units per mL (CFU/mL), was observed against each
fungal isolate after 24 h incubation with NapFFKK-OH at concentrations corresponding to hydrogel
formation (≥1% w/v). A 3 log10 CFU/mL reduction, commonly employed as a marker for antimicrobial
efficacy due to its links with minimum inhibitory concentrations (99.9% reduction in viability) [27],
was also observed at gelation concentrations and above. Aspergillus niger is a significant threat to
immunocompromised patients due to its opportunistic nature and existence as spores throughout
the environment. NapFFKK-OH was able to produce greater than 4 log10 CFU/mL reduction at
concentrations of 0.5% w/v and above (Figure 3). Aspergillus’ role in food spoilage means NapFFKK-OH
may have wider application within the food industry [28]. Future studies relating to NapFFKK-OH’s
efficacy against Aspergillus’ spores and biofilm phenotype would provide useful insight into its wider
application within the pharmaceutical and food industry.
Although several intracellular targets have been identified for fungi, it is likely that
NapFFKK-OH’s main mode of action is via disruption of fungal cell membranes given its
broad-spectrum antimicrobial action [23]. Whilst fungal susceptibility assays demonstrate improved
antifungal activity at gelation concentrations (≥1% w/v), this is likely to be concentration-dependent.
Previous studies have shown a link between nanofibre formation and improved antimicrobial
activity. The establishment of β-sheet secondary structures has been associated with an increase in
peptide amphipathicity, which may enable specific targeting of anionic components within the fungal
cell membrane [29]. Recent research has also hypothesised that hydrogel assembly, conformation,
mechanical properties and molecular folding may be of importance in determining whether hydrogels
possess antimicrobial selective activity via improved interactions with and suctioning of anionic cell
membrane components [30–32]. As with the β-hairpin peptide hydrogels of the Schneider group [33],
a combination of localised cationic charge throughout the porous network and hydrogel surface
(Figure 2) is likely to be responsible for NapFFKK-OH’s broad spectrum antifungal and antimicrobial
efficacy [23]
Similar to mammalian cells, an overall neutral charge is associated with fungal cell membranes
due to the predominance of sterols (ergosterol in fungi and cholesterol in mammals). However,
the presence of local pockets of anionic charge may lead to greater selectivity for fungal membranes
compared to mammalian cells. The cationic charge of peptides is important to facilitate binding with
anionic charged cell wall/membrane components, including mannoproteins present in yeasts such
as Candida [29]. Fungi also possess a cell wall composed of mainly polysaccharides such as glucan,
chitin, mannan and laminarin in Candida. Wang and colleagues recently demonstrated that the cationic
peptide Polybia-MPI, isolated from wasp venom, could selectively bind to laminarin present on the cell
wall surface of Candida glabrata and may also serve as a target for NapFFKK-OH, leading to membrane
permeabilisation and/or disruption [34]. Previously observed insensitivity to cationic antimicrobial
peptides, histatin-5 and magainin, by Candida glabrata was not observed for NapFFKK-OH at the
concentrations employed in this study with greater than 7 log10 CFU/mL reduction against ATCC
2001 at concentrations of 0.5% w/v and above (Figure 7) and total kill against ATCC 90030 at 2% w/v
(Figure S6) [35]. The interaction between antimicrobial peptides and fungal membranes is complex,
especially given the eukaryotic similarities to mammalian membranes, and to date they have not been
satisfactorily elucidated.
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Figure 3. Fungal viability counts (Log10 CFU/mL) of Aspergillus niger CABI 017454 after 24 h exposure
to NapFFKK-OH. Black line represents negative growth control (fungi only). *: p < 0.05, **: p < 0.01
significant difference between Log10 CFU/mL NapFFKK-OH treatment and the negative control.
Figure 4. Fungal viability counts (Log10 CFU/mL) of Candida albicans NCTC 3179 after 24 h exposure
to NapFFKK-OH. Black line represents negative growth control (fungi only). ****: p < 0.0001 significant
difference between Log10 CFU/mL NapFFKK-OH treatment and the negative control.
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Figure 5. Fungal viability counts (Log10 CFU/mL) of Candida parapsilosis ATCC 22019 after 24 h
exposure to NapFFKK-OH. Black line represents negative growth control (fungi only). NS: no
significant difference (p ≥ 0.05), **: p < 0.01, ****: p < 0.0001 significant difference between Log10
CFU/mL NapFFKK-OH treatment and the negative control.
Figure 6. Fungal viability counts (Log10 CFU/mL) of Candida dubliniensis DC24 9 after 24 h exposure to
NapFFKK-OH. Black line represents negative growth control (fungi only). ****: p < 0.0001 significant
difference between Log10 CFU/mL NapFFKK-OH treatment and the negative control.
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Figure 7. Fungal viability counts (Log10 CFU/mL) of Candida glabrata ATCC 2001 after 24 h exposure to
NapFFKK-OH. Black line represents negative growth control (fungi only). **: p < 0.01, ****: p < 0.0001
significant difference between Log10 CFU/mL NapFFKK-OH treatment and the negative control.
2.3. Mammalian Cell Cytotoxicity and Viability
Cell cytotoxicity and viability of NapFFKK-OH against NCTC 929 subcutaneous cells and
ARPE-19 retinal epithelium cells were established using CellTiter 96® AQueous One Solution
(Promega, Southampton, UK) and LIVE/DEAD® viability/cytotoxicity fluorescent (Thermo Fisher
Scientific (Waltham, MA, USA) assays. NCTC 929 was employed as an International Organisation for
Standardisation (ISO) cell line commonly utilised within biomaterial and medical device in vitro
toxicity testing. ARPE-19 cells were used as a comparator ocular derived cell line, providing
preliminary data for assessing NapFFKK-OH’s feasibility as a topical formulation for treating fungal
ocular infections. Naphthalene was purposely chosen as an aromatic driver of hydrogelation within
NapFFKK-OH due to a more established safety profile relative to similarly employed groups, for
example the fluorenylmethyloxycarbonyl (Fmoc) moiety [25,36]. Concentrations tested were in the
micromolar range (µM), representative of sustained breakdown of NapFFKK-OH at infected sites (e.g.,
due to enzymatic proteases) and subsequent exposure of cells to solubilised NapFFKK-OH. Previous
work by our group demonstrated that NapFFKK-OH hydrogels possess over 80% cell viability (NCTC
929, 24 h) at 1% w/v [23]. Xu’s group established that NapFF has greater than 90% viability at 200 µM
against HeLa cells [36]; however, it was important to establish whether cytotoxicity was affected by the
increase in cationic character provided by the addition of two lysines to NapFF. No significant toxicity
was demonstrated in the micromolar range (up to 1000 µM) against either NCTC 929 (Figure 8) or
ARPE-19 cells (Figure S7) using MTS viability reagent after 24 h. However, after 48 h incubation with
ARPE-19 cells, viability was reduced to its lowest observed value of 78.4% (1000 µM), with significant
toxicity demonstrated for NapFFKK-OH at concentrations of 200 µM. This is just below ISO’s own 80%
cell viability threshold value commonly accepted as biocompatible for in vitro studies. It is likely that
prolonged 48 h exposure to cationic NapFFKK-OH results in disruption of mammalian membranes.
No significant haemolysis was observed for NapFFKK-OH after exposure to equine erythrocytes, with
a negligible value of <2% haemolysis observed at concentrations up to 500 µM (Figure S8). This serves
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as a useful indicator of the peptide’s ability to perturb mammalian cell membranes. A LIVE/DEAD®
assay employed alongside fluorescent microscopy confirmed NapFFKK-OH’s high cell compatibility
after 24 h, evidenced by the propensity of green staining due to the conversion of calcein AM to calcein
by viable NCTC 929 cells at concentrations up to 500 µM (Figure 9). Cell images obtained by optical
microscopy (Figure S9) showed the presence at these concentrations of healthy NCTC 929 cells, which
possessed arm-like projections associated with viable cells, enabling them to adhere to microtitre plates.
Overall, these results suggest that NapFFKK-OH, like the majority of other antimicrobial peptide
formulations currently within clinical trials [37], has the greatest promise as a topical therapy.
Figure 8. Percentage cell viability of NCTC clone 929 (ATCC CCL-1) cells after 24 h exposure to varying
concentrations of NapFFKK-OH using CellTiter 96® AQueous One Solution assay. NS: no significant
(p ≥ 0.05) difference between NapFFKK-OH treatment and the negative control.
Figure 9. Cont.
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Figure 9. LIVE/DEAD® fluorescence of NCTC 929 cells with (a) 20 µM; (b) 100 µM; (c) 200 µM;
(d) 500 µM of NapFFKK-OH. Green staining indicates live cells, red staining indicates dead cells.
Each image was taken after 24 h incubation with NapFFKK-OH, scale bar: (a–c) = 400 µm (d) = 200 µm.
3. Conclusions
In conclusion, NapFFKK-OH represents an innovative formulation with the ability to form
nanofibrous structures with inherent antifungal and hydrogel forming properties. Possessing such
functionalities within a single molecular motif is important in order to overcome the formulation
issues (drug loading, solubility) associated with current antifungal topical therapies. These limit
the concentration of antifungal drug that can be delivered to infected sites, resulting in treatment
failure and the survival/spread of exposed fungal isolates with increased resistance characteristics.
NapFFKK-OH acts as a broad-spectrum antimicrobial, having previously been proven by our
group to possess bactericidal action against planktonic and biofilms forms of Gram-positive and
Gram-negative bacteria implicated in medical device infection [23]. Collectively, these observations
suggest that NapFFK-OH antimicrobial activity is due to the targeting of cell membranes. Future work
should focus on tailoring the primary peptide structure to selectively target only specific pathogenic
fungal or bacterial species. It is increasingly becoming the view within modern medicine that
broad-spectrum eradication of microbial flora is undesirable. Previous studies have suggested that
modifying the lipophilic component of peptides with cholesterol and vitamin E results in compounds
with unique antifungal activity [38]. This may be one avenue to explore if hydrogel-forming
ability can be maintained. Similar to many other antimicrobial peptides, NapFFKK-OH may also
prove to have synergistic benefits when combined with existing antifungal therapy, leading to
reduced dosing, side effects and enhanced antifungal efficacy. The low molecular weight, ultrashort
nature of NapFFKK-OH means it would be relatively cost-effective to upscale its manufacture
to clinically relevant pharmaceutical production compared to larger-chain antimicrobial peptides
isolated from biological sources. Significant challenges exist relating to the development of peptide
therapies, especially as unfavourable biological stability and toxicity profiles limit their wider
systemic administration. However, this work provides an important example of an ultrashort
peptide hydrogelator that may contribute to the development of future antifungal and antimicrobial
nanomaterial therapies for topical and biomaterial applications (wound dressings, medical devices).
This is especially relevant given the increasing resistance to standardly employed antifungals and lack
of alternative therapies available to healthcare professionals and patients.
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4. Materials and Methods
4.1. Materials
Fmoc and Boc protected amino acids, N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium
hexafluorophosphate (HBTU), N,N-diisopropylethylamine (DIEA) 1-hydroxybenzotriazole
(HOBt) and Wang resin (mesh size 100–200, 0.65 mmol/g) were obtained from
Novabiochem, Merck KGaA (Darmstadt, Germany). LIVE/DEAD® Viability/Cytotoxicity
fluorescent assay was supplied by Thermo Fisher Scientific (Waltham, MA,
USA). CellTiter 96® AQueous One Solution, containing the cell viability reagent
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS), was purchased from Promega (Southampton, UK). 37% Hydrochloric acid (HCl), acetonitrile
(HPLC grade, ≥99.93%), 2-naphthaleneacetic acid (>99% purity), Whatman pH indicator paper
(pH 1–14), was obtained from Sigma-Aldrich (Gillingham, UK). Sterile Nunc 96-well microtitre plates
and sodium hydroxide (NaOH) ≥99.0% pellets were purchased from VWR International (Lutterworth,
UK). NCTC clone 929 (ATCC CCL-1) murine fibroblast subcutaneous connective tissue cells and
ARPE-19 human retinal pigmented epithelium cells (ATCC CRL-2302) were sourced from LGC
Standards (London, UK). Fresh defibrinated equine erythrocytes were purchased from Laboratory
Supplies & Instruments Ltd. (Antrim, UK). Aspergillus niger CABI 017454, Candida glabrata ATCC
2001, Candida glabrata ATCC 90030, Candida albicans NCYC 610, Candida albicans NCTC 3179,
Candida parapsilosis ATCC 22019, Candida dubliniensis NDC19 (isolated from the mouth of a
non-diabetic patient) and Candida dubliniensis DC24 9 (isolated from the mouth of a diabetic patient)
were kindly donated by Dr Fionnuala Lundy, School of Medicine, Dentistry and Biomedical Sciences,
Queen’s University Belfast.
4.2. Methods
4.2.1. Synthesis
NapFFKK-OH peptide was synthesised using standard Fmoc solid-phase peptide methods and
using a nitrogen bubbler apparatus, as previously outlined by our group [23]. Wang resin preloaded
with Fmoc–Lys(Boc)-OH,) (Novabiochem, Merck KGaA, Darmstadt, Germany) was utilized to produce
carboxylic acid terminated NapFFKK-OH, upon cleavage with a mixture of 95% v/v trifluoracetic
acid, 2.5% v/v triisopropylsilane and 2.5% v/v thioanisole for 3 h at room temperature. Standard
HBTU coupling with DIEA and HOBt was performed in dimethylformamide (DMF) with 4-fold molar
excess of DIEA and 3-fold excess of Fmoc-protected amino acid or 2-naphthaleneacetic acid used
for coupling for 3 h at room temperature. Peptide precipitation was achieved in cold diethyl ether
−20 ◦C). Crude product was dissolved in ethyl acetate and subjected to a series of washes with 1 mM
HCl (3 × 50 mL) and water (3 × 50 mL) and dried over anhydrous magnesium sulphate (MgSO4).
NapFFKK-OH identity was confirmed using electrospray mass spectroscopy (Figure S1) (Thermo
Finnigan LCQ Deca ion trap, Thermo Fisher Scientific) and 1H NMR analysis (Figure S2) (Varian Unity
Inova 400 spectrometer, Varian systems, Palo Alto, CA, USA) in d6-DMSO. NapFFKK-OH purity was
determined by reverse-phase HPLC (Agilent 1260 series, Agilent Technologies Ltd., Cork, Ireland),
using a Gemini C18 column (250 mm × 4.6 mm) with a flow rate of 1.5 mL min−1 and gradient of
2–60% acetonitrile (30 min) in 0.05% TFA–water. NapFFKK-OH was found to have a purity greater
than 95% (Figure S3).
4.2.2. Hydrogel Formulation
Homogenous NapFFKK-OH hydrogels were prepared using a method of pH-triggered induction.
NapFFKK-OH peptide powder is dissolved at higher pH (~9) upon titration with NaOH due to
ionisation of the carboxylic acid groups and hydrogel formation proceeds after subsequent titration
to pH 7.4 and reattachment of H+ to the carboxylate anion (COO−) using HCl. The steps required to
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formulate of 2% w/v NapFFKK-OH hydrogels are outlined in Table 1. Changes in pH were monitored
using Whatman pH paper. Minimum gelation concentration (% w/v) was defined as the lowest
concentration of NapFFKK-OH that formed a self-supporting hydrogel, observed via a gel inversion
assay after 24 h development. Previously reported values by our group of 1% w/v minimum gelation
concentration for NapFFKK-OH were confirmed [23].
Table 1. Stepwise formulation of a self-assembling pH-triggered 2% w/v NapFFKK-OH (500 µL).
Formulation Step Constituent Quantity
1 NapFFKK-OH 10 mg pre-weighed
2 Deionised H2O 200 µL (in 50 µL aliquots)
3 1 M NaOH 50 µL (in 10 µL aliquots)
4 Deionised H2O 200 µL (in 50 µL aliquots)
5 0.5 M HCl 20 µL (in 10 µL aliquots)
6 Deionised H2O To 500 µL
4.2.3. Scanning Electron Microscopy
NapFFKK-OH hydrogels were formulated as outlined above (Table 1). 80 µL of NapFFKK-OH
hydrogel was pipetted onto the SEM sample mount using a Gilson Microman E positive displacement
pipette (Gilson, Birmingham, UK) and subjected to flash freezing in liquid nitrogen and freeze dried.
A JEOL JSM 6500 F SEM (JEOL, Freising, Germany) was used for SEM imaging at 3 kV, with each
sample pre-coated with an 8 nm layer of gold.
4.2.4. Fungal Susceptibility Assay
The ability of NapFFKK-OH to reduce fungal viability was assessed using a colony count
assay adapted from a method previously utilised by our group [24]. Aspergillus niger CABI
017454, Candida glabrata ATCC 2001, Candida glabrata ATCC 90030, Candida albicans NCYC 610,
Candida albicans NCTC 3179, Candida parapsilosis ATCC 22019, Candida dubliniensis NDC19 and
Candida dubliniensis DC24 9 were inoculated and allowed to grow for 18–24 h at 37 ◦C in Sabouraud
dextrose broth) containing chloramphenicol 0.05 g/L. The optical density was adjusted to 0.15 at
530 nm to 2 × 106 CFU/mL in Sabouraud dextrose broth to prepare a working suspension of fungi,
and 100 µL of this was added to a 96-well microtiter plate and challenged with a range (0.5–2.0%
w/v) of NapFFKK-OH concentrations formulated as in Table 1. One hundred microliters of each
concentration of NapFFKK-OH was transferred to the microtiter plate using a Gilson Microman
E positive displacement pipette. The positive control consisted of 100 µL of the working fungal
suspension and 100 µL of PBS. The negative control consisted of 100 µL of sterile Sabouraud dextrose
broth and 100 µL of pH 7.4 PBS. The challenge plates, containing NapFFKK-OH, were incubated for
24 h at 37 ◦C and viable counts obtained via Miles and Misra counting after plating 10 µL samples
from the challenge plates on Sabouraud dextrose agar. Results were displayed as the mean (Log10
CFU/mL) of three replicates and tests were performed in triplicate.
4.2.5. Cell Cytotoxicity and Viability Assays
Mammalian cell cytotoxicity was assessed using murine fibroblast subcutaneous connective tissue
NCTC clone 929 (ATCC CCL-1) and ARPE-19 retinal pigmented epithelium cells (ATCC CRL-2302) cell
lines. NCTC 929 cells were cultured in Eagle’s Minimum Essential Medium (MEM) containing phenol
red with Earle’s Salts and L-glutamine, supplemented with 10% horse serum (Invitrogen, Paisley,
UK). ARPE-19 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10%
foetal bovine serum. Cells were grown at 37 ◦C and 5% CO2 and subcultured at 80–90% confluency.
Subculturing involved the removal of spent media, washing with sterile PBS, and detachment of cell
monolayers with 0.05% trypsin/0.53 mM disodium ethylenediaminetetraacetate dihydrate solution.
Cells were cultured until at least third passage and inoculated at 1 × 104 cells per well in a 96-well
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microtitre plate and incubated for 24 h. The medium was then removed and the cells exposed to
100 µL of a range of NapFFKK-OH concentrations (20–500 µM) for 24 h. Control wells included
media only (100% viability, negative control) and 70% ethanol treated cells (100% kill, positive
control). A LIVE/DEAD® viability/cytotoxicity fluorescent assay was used alongside fluorescence
microscopy (EVOS FL microscope) to assess cell viability. Following a 24 h incubation with each
NapFFKK-OH concentration, NCTC 929 cells were incubated for 20 min with a mixture of 4 mM
ethidium homodimer-1 and 2 mM calcein AM in pH 7.4 PBS. Viable cells were stained green due
to the conversion of calcein AM to calcein, whilst nonviable cells were stained red due to ethidium
homodimer-1. Three randomly chosen areas were selected for analysis. Cell cytotoxicity was also
analysed using a MTS containing CellTiter 96® AQueous One Solution viability assay. Cells were
cultured as outlined above and following 24 h exposure to NapFFKK-OH, cell viability was assessed
using MTS and allowed to develop for 1 h. Absorption was measured at 570 nm using a Tecan
Sunrise plate reader (Tecan UK Ltd., Reading, UK). Cell viability was calculated using Equation (1)
and reported as the mean of six replicates:
% Cell viability = [(Absorbance570nm peptide treated− Absorbance570nm negative
control)/(Absorbance570nm positive control − Absorbance570nm negative control) × 100]. (1)
4.2.6. Haemolysis Assay
NapFFKK-OH was assessed spectrophotometrically for its ability to induce haemoglobin release
from fresh equine erythrocytes according to the method previously utilized by our group [18].
Fresh defibrinated equine erythrocytes were washed three times with equal volumes of PBS.
After centrifugation for 15 min at 900× g, erythrocytes were resuspended 4% v/v in PBS. Equal volumes
(100 µL) of the erythrocyte suspension were added to each well of a 96-well microtitre plate.
Erythrocytes were subsequently exposed to varying concentrations of peptide, incubated at 37 ◦C for
1 h and centrifuged at 1000× g for five minutes. Aliquots of the supernatant were transferred to a fresh
96-well microtiter plate, and haemoglobin release measured spectrophotometrically at 405 nm using a
Tecan Sunrise plate reader. As a positive control (100% haemolysis), erythrocytes were treated with 10%
Triton X-100, whilst PBS (0% haemolysis) acted as the negative control. Results for all concentrations
are reported as the mean of six replicates. Percentage haemolysis was calculated using Equation (2)
below:
% Haemolysis = [(Absorbance405nm peptide − Absorbance405nm negative PBS
control)/(Absorbance405nm 10% Triton X − Absorbance405nm negative PBS control) × 100]. (2)
4.2.7. Statistical Analysis
Statistical analyses were performed using Microsoft Excel 2013 (Microsoft, Redmond, WA, USA)
and GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). Standard deviations were obtained at
each concentration of NapFFKK-OH based on nine replicates (three replicates performed in triplicate)
for quantitative fungal viability assays and mean values obtained. For cell cytotoxicity assays standard
deviations and mean values were also obtained from six replicates at each concentration. Statistical
analyses were employed using a one-way Analysis of Variance (ANOVA) and a Tukey–Kramer multiple
comparisons test used to identify individual differences between a reduction in fungal viability for
NapFFKK-OH relative to the negative PBS control. Similarly ANOVA was also utilised for statistical
analysis of cell cytotoxicity data by comparison of percentage viability (MTS) for the NapFFKK-OH
employed to the medium-only negative control (100% viability). Haemolysis data were compared by
the same statistical method with percentage haemolysis compared to the PBS, negative, non-haemolytic,
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control (0% haemolysis). ANOVAs were employed rather than parametric Kruskal–Wallis tests as the
data were demonstrated to be normally distributed using the Kolmogorov and Smirnov method. In all
cases a probability of p < 0.05 denoted significance.
Supplementary Materials: The following are available online at www.mdpi.com/link, Figure S1: Mass spectra
NapFFKK-OH, Figure S2: 1H NMR of NapFFKK-OH, Figure S3: HPLC trace NapFFKK-OH, Figure S4: Fungal
viability counts (Log10 CFU/mL) of Candida albicans NCYC 610 after 24 h exposure to NapFFKK-OH, Figure S5:
Fungal viability counts (Log10 CFU/mL) of Candida dubliniensis NDC19 after 24 h exposure to NapFFKK-OH,
Figure S6: Fungal viability counts (Log10 CFU/mL) of Candida glabrata ATCC 90030 after 24 h exposure to
NapFFKK-OH, Figure S7: Percentage cell viability of ARPE-19 retinal pigmented epithelium cells (ATCC
CRL-2302) after 24 h exposure to varying concentrations of NapFFKK-OH, Figure S8: Percentage haemolysis of
equine erythrocytes after 1 h exposure to varying concentrations of NapFFKK-OH, Figure S9: Optical images of
NCTC 929 cells with NapFFKK-OH.
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